ESR1 and breast carcinoma: Conversely, ER-positive low grade breast carcinoma with low proliferation (Ki67 < 14 %) showed the lowest level expression of EZH2, with only 18.5 % (10/54) overexpressing EZH2; no case in this group showed diffuse strong overexpression (Table 3).